Kapiva is currently operating at an annual revenue run rate (ARR) of Rs 550 crore, up from Rs 350 crore in FY25, reflecting strong consumer adoption across categories and channels Bengaluru-based ...

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

The changes to the citizenship process signal a shift toward stricter vetting. In a press release, USCIS said the changes were part of "an ongoing effort to restore integrity to the naturalization ...

BOSTON - The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Vertex Pharmaceuticals’ (NASDAQ:VRTX) povetacicept for the treatment of IgA nephropathy, a serious kidney ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...

Copy the link and send it by email, chat, or embed it on a website. Optionally, share via QR code, email invite, or embed code for wider access. If you want to improve the flow of your surveys, check ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...